NV40 Stock Chart & Stats
€0.29
--
Market closed
€0.29
--
Day’s Range― - ―
52-Week Range€0.28 - €0.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€16.98M
Enterprise Value€5.85
Total Cash (Recent Filing)€8.35M
Total Debt (Recent Filing)€1.53M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Aug 19, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.11Price Target Upside3386.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Phase IIb EfficacyThe strong, durable CLOVER WaM Phase IIb outcomes (high ORR, long DOR and PFS) materially strengthen the clinical predicate for regulatory approval. These results lower scientific risk, support accelerated approval and justify a pivotal Phase III design, improving long-term commercialization prospects if confirmed.
Clear Regulatory Path And Breakthrough StatusA defined accelerated-approval strategy plus Breakthrough Therapy designation creates a structured regulatory route and potential for expedited review. This reduces approval timeline uncertainty, aids protocol alignment with FDA, and increases the likelihood of efficient confirmatory study execution and earlier market access.
Low Absolute Debt BurdenMinimal debt reduces fixed financial obligations, lowering insolvency and interest coverage pressure during costly late-stage development. This structural advantage preserves flexibility to prioritize financing for trials and commercialization without near-term creditor constraints, improving strategic optionality.
Bears Say
Pre-revenue With Sustained Cash BurnAs a pre-revenue biotech with persistent negative operating and free cash flow, the company must continually raise external capital to fund trials and operations. This structural cash consumption increases funding risk, limits reinvestment capacity, and makes long-term program continuity contingent on successful financing and clinical progress.
Eroded Equity And Dilution RiskSignificant equity erosion over time and recent shareholder approvals to increase share authorization and enable warrant exercises create a strong predisposition toward dilutive financing. Persistent dilution undermines per-share economics and can hamper ability to attract capital on favorable terms over the medium term.
Milestone‑contingent Financing UncertaintyA large portion of pledged funding depends on clinical/regulatory milestones and market trading conditions, linking capital availability to execution and market performance. If milestones or market thresholds are unmet, runway could shorten, forcing hurried financings, greater dilution or program delays—material operational risk.
Cellectar Biosciences News
NV40 FAQ
What was Cellectar Biosciences Inc’s price range in the past 12 months?
Cellectar Biosciences Inc lowest stock price was €0.28 and its highest was €0.29 in the past 12 months.
What is Cellectar Biosciences Inc’s market cap?
Cellectar Biosciences Inc’s market cap is €16.98M.
When is Cellectar Biosciences Inc’s upcoming earnings report date?
Cellectar Biosciences Inc’s upcoming earnings report date is Aug 19, 2026 which is in 21 days.
How were Cellectar Biosciences Inc’s earnings last quarter?
Cellectar Biosciences Inc released its earnings results on May 14, 2026. The company reported -€1.168 earnings per share for the quarter, beating the consensus estimate of -€1.655 by €0.487.
Is Cellectar Biosciences Inc overvalued?
According to Wall Street analysts Cellectar Biosciences Inc’s price is currently Undervalued.
Does Cellectar Biosciences Inc pay dividends?
Cellectar Biosciences Inc does not currently pay dividends.
What is Cellectar Biosciences Inc’s EPS estimate?
Cellectar Biosciences Inc’s EPS estimate is -0.46.
How many shares outstanding does Cellectar Biosciences Inc have?
Cellectar Biosciences Inc has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences Inc’s price movement after its last earnings report?
Cellectar Biosciences Inc reported an EPS of -€1.168 in its last earnings report, beating expectations of -€1.655. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectar Biosciences Inc?
Currently, no hedge funds are holding shares in DE:NV40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences Inc
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
NV40 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.View all DE:NV40 earnings summariesNV40 Stock 12 Month Forecast
Average Price Target
€10.11
▲(3386.68% Upside)